Research News
View articles by month and year
11–18 of 18 articles
-
Taxanes Only Reduce Recurrence Risk for Certain Types of Breast Cancer
Research shows that taxanes (a type of chemotherapy medicine) reduce the risk of recurrence of only certain types of breast cancer, so using taxanes to treat the other types of disease doesn't offer any real benefits.
-
New Chemo Meds Improve Survival for Women with Advanced-Stage Disease
Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.
-
Xeloda and Avastin Combo Better Than Xeloda Alone for Metastatic Disease
The combination of Xeloda (chemical name: capecitabine) and Avastin (chemical name: bevacizumab) has been shown to stop metastatic breast cancer from growing longer than Xeloda alone.
-
Taxol Added to Chemo Combination Improved Survival of Women Diagnosed with Early-Stage Breast Cancer
After surgery to treat early-stage breast cancer, women who got Taxol after the FEC (fluorouracil, Ellence, Cytoxan) chemotherapy combination were more likely to be alive and cancer-free 5 years after diagnosis than women who got only FEC.
-
Taxol Weekly Better Than Every Three Weeks for Breast Cancer
Getting Taxol (chemical name: placlitaxel) every week seems to have more benefits than getting it every 3 weeks or getting Taxotere (chemical name: docetaxel) on either schedule.
-
Taxotere Combo Improves Survival
The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.
-
Some Women Don’t Benefit from Adding Taxol to Chemo Regimen
An early breast cancer's HER2 status affects the benefits offered by Taxol.
-
New Chemo Medicines Treat Metastatic Disease
Average survival times for women diagnosed with metastatic breast cancer are increasing because of new medications.
11–18 of 18 articles
